Access DB# 79122

SEARCH REQUEST FORM

Scientific and Technical Information Center

(571) 3:05 pm

Requester's Full Name: JANE ZARA Examiner #: 77512 Date: 7/16/04

Art Unit: 1635 Phone Number ~~30~~ 2-0765 Serial Number: 10/010,568

Mail Box and Bldg/Room Location: 2C03 Results Format Preferred (circle): PAPER DISK E-MAIL

2618

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Novel Human G protein

Inventors (please provide full names): Ransetten et al.

Earliest Priority Filing Date: 12/7/01

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please Search Seq ID No: 5/:
EXACT match needed. [100 NT. size limit
(No interference search please.)

Please Search Seq ID No 1.
Please limit size. to betw 100 - 50 NT.
Score over length if necessary.
80% cutoff Thanks.

No interference plsd.

****

STAFF USE ONLY	Type of Search		Vendors and cost where applicable
Searcher: D. Schreiber	NA Sequence (#) 12		STN
Searcher Phone #: 272-2526	AA Sequence (#)		Dialog
Searcher Location: Remsen 5D18	Structure (#)		Questel/Orbit
Date Searcher Picked Up:	Bibliographic		Dr.Link
Date Completed: 7/26	Litigation		Lexis/Nexis
Searcher Prep & Review Time: 15	Fulltext		Sequence Systems Computer
Clerical Prep Time:	Patent Family		WWW/Internet
Online Time: 101	Other		Other (specify)

EIC 1500 (8-01)

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: JANE ZARA Examiner #: 77512 Date: 7/16/04
Art Unit: 1635 Phone Number ~~30~~ 2-0765 Serial Number: 10/019,568
Mail Box and Bldg/Room Location: 2C03 Results Format Preferred (circle): PAPER DISK E-MAIL
2C18

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Novel Human G-protein

Inventors (please provide full names): Ramsdell et al.

Earliest Priority Filing Date: 12/7/01

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please Search Seq ID No: 5/ [100 NT. size limit]
EXACT match needed.
(No interference search please.)

Please Search Seq ID No 1.
Please limit size. to between 10 - 50 NT.
Some over length if necessary.
No interference please.
Thanks.

****

STAFF USE ONLY	Type of Search		Vendors and cost where applicable
Searcher: _____	NA Sequence (#)_____		STN _____
Searcher Phone #: _____	AA Sequence (#)_____		Dialog _____
Searcher Location: _____	Structure (#)	_____	Questel/Orbit _____
Date Searcher Picked Up: _____	Bibliographic	_____	Dr.Link _____
Date Completed: _____	Litigation	_____	Lexis/Nexis _____
Searcher Prep & Review Time: _____	Fulltext	_____	Sequence Systems _____
Clerical Prep Time: _____	Patent Family	_____	WWW/Internet _____
Online Time: _____	Other	_____	Other (specify) _____

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: July 26, 2004, 09:15:49 ; Search time 1 Seconds
(without alignments)
5.092 Million cell updates/sec

Title: US-10-010-568-1
Perfect score: 1081
Sequence: 1 catattgccaaactgaactc.....ccttgaaatatttcatttac 1081

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 125 seqs, 2355 residues

Total number of hits satisfying chosen parameters: 250

Minimum DB seq length: 10
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 129 summaries

Database : rge1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	33	3.1	33	1	AX464563	ACCESSION:AX464563
	2	33	3.1	33	1	BD187508	ACCESSION:BD187508
c	3	30	2.8	30	1	AX464564	ACCESSION:AX464564
c	4	30	2.8	30	1	BD187509	ACCESSION:BD187509
c	5	27.8	2.6	32	1	BD171273	ACCESSION:BD171273
c	6	27.8	2.6	32	1	BD184764	ACCESSION:BD184764
	7	27	2.5	32	1	BD171272	ACCESSION:BD171272
	8	27	2.5	32	1	BD184763	ACCESSION:BD184763
	9	26	2.4	26	1	AX662013	ACCESSION:AX662013
	10	26	2.4	26	1	AX675933	ACCESSION:AX675933
	11	25.4	2.3	27	1	AX593363	ACCESSION:AX593363
c	12	25	2.3	25	1	AX482510	ACCESSION:AX482510
c	13	25	2.3	25	1	AX482511	ACCESSION:AX482511
c	14	25	2.3	25	1	AX482512	ACCESSION:AX482512
c	15	25	2.3	25	1	AX482513	ACCESSION:AX482513
c	16	25	2.3	25	1	AX482514	ACCESSION:AX482514
	17	25	2.3	30	1	AX662016	ACCESSION:AX662016
c	18	24	2.2	24	1	AX148227	ACCESSION:AX148227
	19	23	2.1	23	1	AX148226	ACCESSION:AX148226
	20	23	2.1	23	1	AX148278	ACCESSION:AX148278
c	21	23	2.1	23	1	AX148279	ACCESSION:AX148279
	22	22	2.0	22	1	AX458269	ACCESSION:AX458269
	23	22	2.0	22	1	AX662012	ACCESSION:AX662012
c	24	22	2.0	22	1	AX662014	ACCESSION:AX662014
c	25	22	2.0	22	1	AX662017	ACCESSION:AX662017
	26	22	2.0	22	1	AX675932	ACCESSION:AX675932
c	27	22	2.0	22	1	AX675934	ACCESSION:AX675934
	28	21	1.9	25	1	AX147876	ACCESSION:AX147876
	29	21	1.9	25	1	AX521925	ACCESSION:AX521925
c	30	20	1.9	20	1	AX458270	ACCESSION:AX458270
	31	20	1.9	20	1	AX458271	ACCESSION:AX458271
c	32	20	1.9	20	1	AX458272	ACCESSION:AX458272
	33	19.4	1.8	21	1	AX147875	ACCESSION:AX147875
	34	19.4	1.8	21	1	AX147900	ACCESSION:AX147900
	35	19.4	1.8	21	1	AX147929	ACCESSION:AX147929
	36	19.4	1.8	21	1	AX521924	ACCESSION:AX521924
	37	19.4	1.8	21	1	AX521949	ACCESSION:AX521949
	38	19.4	1.8	21	1	AX521978	ACCESSION:AX521978
c	39	19	1.8	19	1	AX147874	ACCESSION:AX147874
c	40	19	1.8	19	1	AX147898	ACCESSION:AX147898
c	41	19	1.8	19	1	AX147927	ACCESSION:AX147927
c	42	19	1.8	19	1	AX521923	ACCESSION:AX521923
c	43	19	1.8	19	1	AX521947	ACCESSION:AX521947
c	44	19	1.8	19	1	AX521976	ACCESSION:AX521976
c	45	16	1.5	17	1	AX730196	ACCESSION:AX730196
	46	15.4	1.4	19	1	I46729	ACCESSION:I46729
c	47	14.8	1.4	18	1	AR151351	ACCESSION:AR151351
c	48	14.8	1.4	18	1	AR151366	ACCESSION:AR151366
	49	14.8	1.4	18	1	AR295560	ACCESSION:AR295560
	50	14.4	1.3	17	1	AR329420	ACCESSION:AR329420
c	51	14.4	1.3	17	1	AX580260	ACCESSION:AX580260
c	52	14.4	1.3	17	1	AX732335	ACCESSION:AX732335
	53	14.4	1.3	18	1	AR131571	ACCESSION:AR131571
	54	14.4	1.3	18	1	AR199505	ACCESSION:AR199505
	55	14.4	1.3	18	1	AR200976	ACCESSION:AR200976
	56	14.4	1.3	18	1	AX403678	ACCESSION:AX403678
	57	14.4	1.3	18	1	AX419727	ACCESSION:AX419727
	58	14.4	1.3	18	1	BD084989	ACCESSION:BD084989
c	59	14	1.3	17	1	AX759618	ACCESSION:AX759618
c	60	13.8	1.3	17	1	AR192109	ACCESSION:AR192109
c	61	13.8	1.3	17	1	AR325989	ACCESSION:AR325989
c	62	13.8	1.3	17	1	AR327329	ACCESSION:AR327329
	63	13.8	1.3	17	1	AX215806	ACCESSION:AX215806
	64	13.8	1.3	17	1	AX215907	ACCESSION:AX215907
c	65	13.8	1.3	17	1	AX616054	ACCESSION:AX616054
c	66	13.8	1.3	17	1	AX673314	ACCESSION:AX673314
	67	13.8	1.3	17	1	AX674342	ACCESSION:AX674342
	68	13.8	1.3	17	1	AX726644	ACCESSION:AX726644
	69	13.8	1.3	17	1	AX728146	ACCESSION:AX728146
	70	13.8	1.3	17	1	AX729859	ACCESSION:AX729859
c	71	13.8	1.3	17	1	AX731349	ACCESSION:AX731349
c	72	13.8	1.3	17	1	AX735339	ACCESSION:AX735339
c	73	13.8	1.3	17	1	AX737591	ACCESSION:AX737591
	74	13.8	1.3	17	1	AX745130	ACCESSION:AX745130
	75	13.8	1.3	17	1	AX745131	ACCESSION:AX745131
	76	13.8	1.3	17	1	AX783575	ACCESSION:AX783575
	77	13.8	1.3	17	1	AX922605	ACCESSION:AX922605
	78	13.8	1.3	17	1	AX922607	ACCESSION:AX922607
c	79	13.8	1.3	17	1	BD104698	ACCESSION:BD104698
	80	13.8	1.3	17	1	BD198831	ACCESSION:BD198831
c	81	13.8	1.3	17	1	BD201054	ACCESSION:BD201054
	82	13.6	1.3	22	1	AX662017	ACCESSION:AX662017
c	83	13.4	1.2	15	1	I39115	ACCESSION:I39115
c	84	13.4	1.2	15	1	AX635363	ACCESSION:AX635363
	85	13	1.2	15	1	I77824	ACCESSION:I77824
	86	13	1.2	15	1	AX638367	ACCESSION:AX638367
c	87	13	1.2	15	1	BD208445	ACCESSION:BD208445
	88	12.8	1.2	16	1	AR027407	ACCESSION:AR027407
	89	12.8	1.2	16	1	AR028861	ACCESSION:AR028861
	90	12.8	1.2	16	1	AR034398	ACCESSION:AR034398
	91	12.8	1.2	16	1	I07582	ACCESSION:I07582
	92	12.8	1.2	16	1	BD104358	ACCESSION:BD104358
c	93	12.6	1.2	22	1	AX458269	ACCESSION:AX458269
	94	12.4	1.1	14	1	AR374278	ACCESSION:AR374278
	95	12.4	1.1	15	1	AR041851	ACCESSION:AR041851
	96	12.4	1.1	15	1	AR041852	ACCESSION:AR041852
	97	12.4	1.1	15	1	AR041853	ACCESSION:AR041853
c	98	12.4	1.1	15	1	AR055975	ACCESSION:AR055975
c	99	12.4	1.1	15	1	AR056107	ACCESSION:AR056107
	100	12.4	1.1	15	1	AR083242	ACCESSION:AR083242
c	101	12.4	1.1	15	1	AR113733	ACCESSION:AR113733
c	102	12.4	1.1	15	1	AR113865	ACCESSION:AR113865
	103	12.4	1.1	15	1	AR177861	ACCESSION:AR177861
	104	12.4	1.1	15	1	E12017	ACCESSION:E12017
c	105	12.4	1.1	15	1	I77422	ACCESSION:I77422
c	106	12.4	1.1	15	1	AX633029	ACCESSION:AX633029

c 107	12.4	1.1	15	1	AX633194	ACCESSION:AX633194
108	12.4	1.1	15	1	AX637349	ACCESSION:AX637349
109	12.4	1.1	15	1	AX637351	ACCESSION:AX637351
110	12.4	1.1	15	1	AX637353	ACCESSION:AX637353
c 111	12.4	1.1	15	1	AX638141	ACCESSION:AX638141
c 112	12.4	1.1	15	1	AX742794	ACCESSION:AX742794
c 113	12.4	1.1	15	1	BD184647	ACCESSION:BD184647
114	12.4	1.1	15	1	BD208299	ACCESSION:BD208299
c 115	12.4	1.1	32	1	BD171272	ACCESSION:BD171272
c 116	12.4	1.1	32	1	BD184763	ACCESSION:BD184763
c 117	12	1.1	12	1	A47643	ACCESSION:A47643
c 118	12	1.1	12	1	AR002979	ACCESSION:AR002979
c 119	12	1.1	12	1	AR027861	ACCESSION:AR027861
120	12	1.1	14	1	A12786	ACCESSION:A12786
121	12	1.1	14	1	AR403521	ACCESSION:AR403521
122	12	1.1	14	1	BD069021	ACCESSION:BD069021
123	12	1.1	15	1	A83397	ACCESSION:A83397
c 124	12	1.1	15	1	I39114	ACCESSION:I39114
c 125	12	1.1	15	1	AR180550	ACCESSION:AR180550
126	12	1.1	15	1	AR206431	ACCESSION:AR206431
c 127	12	1.1	15	1	AX635361	ACCESSION:AX635361
128	12	1.1	15	1	BD083622	ACCESSION:BD083622
c 129	12	1.1	15	1	BD208446	ACCESSION:BD208446

ALIGNMENTS

RESULT 1
AX464563
LOCUS AX464563 33 bp DNA linear PAT 16-JUL-2002
DEFINITION Sequence 3 from Patent EP1219638.
ACCESSION AX464563
VERSION AX464563.1 GI:21899358
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Fidock,M.D.
TITLE G-protein coupled receptors having homology to the p2y
purinoreceptor 1 (p2y1)
JOURNAL Patent: EP 1219638-A 3 03-JUL-2002;
Pfizer Limited (GB) ; Pfizer Inc. (US)
FEATURES Location/Qualifiers
source 1. .33
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 3.1%; Score 33; DB 1; Length 33;
Best Local Similarity 100.0%; Pred. No. 1.8;
Matches 33; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy         51 ACCATGAATGAGCCACTAGACTATTTAGCAAAT 83
              |||||||||||||||||||||||||||||||||
Db          1 ACCATGAATGAGCCACTAGACTATTTAGCAAAT 33
```

RESULT 2
BD187508
LOCUS BD187508 33 bp DNA linear PAT 17-JUL-2003
DEFINITION Novel Polypeptide.
ACCESSION BD187508
VERSION BD187508.1 GI:32997247
KEYWORDS JP 2003024081-A/2.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 33)
AUTHORS Fidock,M.D.
TITLE Novel Polypeptide
JOURNAL Patent: JP 2003024081-A 2 28-JAN-2003;
Pfizer Ltd (EP(GB) only),Pfizer Inc (US JP EP except GB)
COMMENT OS Homo sapiens
PN JP 2003024081-A/2
PD 28-JAN-2003
PF 17-DEC-2001 JP 2001382712
PR 18-DEC-2000 GB 0030854.4,04-MAY-2001 GB 0111031.1 PI
mark david fidock
CC
FH Key Location/Qualifiers.
FEATURES Location/Qualifiers
source 1. .33
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 3.1%; Score 33; DB 1; Length 33;
Best Local Similarity 100.0%; Pred. No. 1.8;
Matches 33; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy         51 ACCATGAATGAGCCACTAGACTATTTAGCAAAT 83
              |||||||||||||||||||||||||||||||||
Db          1 ACCATGAATGAGCCACTAGACTATTTAGCAAAT 33
```

RESULT 3
AX464564/c
LOCUS AX464564 30 bp DNA linear PAT 16-JUL-2002
DEFINITION Sequence 4 from Patent EP1219638.
ACCESSION AX464564
VERSION AX464564.1 GI:21899359
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Fidock,M.D.
TITLE G-protein coupled receptors having homology to the p2y
purinoreceptor 1 (p2y1)
JOURNAL Patent: EP 1219638-A 4 03-JUL-2002;
Pfizer Limited (GB) ; Pfizer Inc. (US)
FEATURES Location/Qualifiers
source 1. .30
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.8%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 3.3;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1038 AAGAAAATTAGTTACTCAAACAACCCTTGA 1067
              ||||||||||||||||||||||||||||||
Db         30 AAGAAAATTAGTTACTCAAACAACCCTTGA 1
```

RESULT 4
BD187509/c
LOCUS BD187509 30 bp DNA linear PAT 17-JUL-2003
DEFINITION Novel Polypeptide.
ACCESSION BD187509
VERSION BD187509.1 GI:32997248
KEYWORDS JP 2003024081-A/3.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 30)
AUTHORS Fidock,M.D.
TITLE Novel Polypeptide
JOURNAL Patent: JP 2003024081-A 3 28-JAN-2003;

```
  INFORMATION FOR SEQ ID NO:  16:
    SEQUENCE CHARACTERISTICS:
      LENGTH:  15
      TYPE:  nucleic acid
      STRANDEDNESS:  single
      TOPOLOGY:  linear
    MOLECULE TYPE:  synthetic
    PUBLICATION INFORMATION:
      RELEVANT RESIDUES IN SEQ ID NO:  16: FROM 1 TO 15
:-09-270-455-16

Query Match              1.1%;  Score 12.4;  DB 1;  Length 15;
Best Local Similarity   92.9%;  Pred. No. 17;
Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

      1064 TTGAAATATTTCAT 1077
           ||| ||||||||||
         1 TTGGAATATTTCAT 14


:SULT 33
-07-936-163-9/c
Sequence 9, Application US/07936163
Patent No. 5743477
 GENERAL INFORMATION:
   APPLICANT:  WALSH, TERENCE A
   APPLICANT:  MERLO, DONALD J
   APPLICANT:  HOUTCHENS, ROBERT A
   APPLICANT:  STRICKLAND, JAMES A
   APPLICANT:  ORR, GREGORY L
   TITLE OF INVENTION:  INSECTICIDAL PROTEINS AND METHOD FOR
   TITLE OF INVENTION:  PLANT PROTECTION
   NUMBER OF SEQUENCES:  49
   CORRESPONDENCE ADDRESS:
     ADDRESSEE:  THOMAS D. ZINDRICK
     STREET:  9002 PURDUE ROAD
     CITY:  INDIANAPOLIS
     STATE:  IN
     COUNTRY:  US
     ZIP:  46268-1189
   COMPUTER READABLE FORM:
     MEDIUM TYPE:  Floppy disk
     COMPUTER:  IBM PC compatible
     OPERATING SYSTEM:  PC-DOS/MS-DOS
     SOFTWARE:  PatentIn Release #1.0, Version #1.25
   CURRENT APPLICATION DATA:
     APPLICATION NUMBER:  US/07/936,163
     FILING DATE:  27-AUG-1992
     CLASSIFICATION:  514
   ATTORNEY/AGENT INFORMATION:
     NAME:  ZINDRICK, THOMAS D
     REGISTRATION NUMBER:  32,185
     REFERENCE/DOCKET NUMBER:  C-38,424A
   TELECOMMUNICATION INFORMATION:
     TELEPHONE:  (517) 636-1869
 INFORMATION FOR SEQ ID NO:  9:
   SEQUENCE CHARACTERISTICS:
     LENGTH:  12 base pairs
     TYPE:  nucleic acid
     STRANDEDNESS:  single
     TOPOLOGY:  linear
 07-936-163-9

uery Match              1.1%;  Score 12;  DB 1;  Length 12;
est Local Similarity   100.0%;  Pred. No. 16;
atches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

       282 TGCACAGATCTG 293
           ||||||||||||
        12 TGCACAGATCTG 1


ULT 34
```

```
US-08-494-301A-3/c
; Sequence 3, Application US/08494301A
; Patent No. 5856461
;  GENERAL INFORMATION:
;    APPLICANT:  Colote, Soudhir
;    APPLICANT:  Pirotzky, Eduardo
;    TITLE OF INVENTION:  Oligonucleotides to Inhibit the
;    TITLE OF INVENTION:  Expression of Isoprenyl Protein Transferases
;    NUMBER OF SEQUENCES:  36
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lucas & Just
;      STREET:  205 E. 42nd Street
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  10017
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.50 inch,
;      MEDIUM TYPE:  1.44 MB storage
;      COMPUTER:  IBM 486 Compatible
;      OPERATING SYSTEM:  MS-DOS 5.0
;      SOFTWARE:  WordPerfect 5.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/494,301A
;      FILING DATE:  23-JUNE-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  GB 9413035.8
;      FILING DATE:  29-JUNE-1994
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  nucleotide
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    ANTI-SENSE:  Yes
US-08-494-301A-3

  Query Match              1.1%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 16;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         786 CTGCTACTCCTT 797
               ||||||||||||
Db          12 CTGCTACTCCTT 1


RESULT 35
US-08-729-601A-71/c
; Sequence 71, Application US/08729601A
; Patent No. 6166302
;  GENERAL INFORMATION:
;    APPLICANT:  Merlo, Donald J.
;    APPLICANT:  Folkerts, Otto
;    TITLE OF INVENTION:  Modified Bacillus Thuringiensis Gene for
;    TITLE OF INVENTION:  Lepidopteran Control in Plants
;    NUMBER OF SEQUENCES:  84
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fitch, Even, Tabin & Flannery
;      STREET:  135 S. LaSalle St.
;      CITY:  Chicago
;      STATE:  IL
;      COUNTRY:  USA
;      ZIP:  60603
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/729,601A
;      FILING DATE:
;      CLASSIFICATION:  800
```

OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 130; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 0 A; 4 C; 8 G; 0 T; 5 U; 0 Other;

Query Match 1.3%; Score 14; DB 1; Length 17;
Best Local Similarity 64.3%; Pred. No. 67;
Matches 9; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 510 GCCTGTGCTGTGGT 523
||||:|:||:|:||:
Db 3 GCCUGUGCUGUGGU 16

RESULT 67
ADB42616/c
ID ADB42616 standard; DNA; 17 BP.
XX
AC ADB42616;
XX
DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #2939.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.

[redacted]-SEP-2001; 2001FR-00011981.

XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 375; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
SQ Sequence 17 BP; 7 A; 2 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 1.3%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 67;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 821 CTTCCATATCTTGA 834
||||||||||||||
Db 16 CTTCCATATCTTGA 3

RESULT 68
AAX74847/c
ID AAX74847 standard; RNA; 17 BP.
XX
AC AAX74847;
XX
DT 28-JUL-1999 (first entry)
XX
DE Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #375.
XX
KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
OS Mus sp.
XX
PN WO9715662-A2
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
XX
PA (RIBO-) RIBOZYME PHARM INC.

PA (CHIR) CHIRON CORP.
XX
PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX
DR WPI; 1997-259017/23.
XX
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 166; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 7 A; 0 C; 7 G; 0 T; 3 U; 0 Other;

Query Match 1.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 70;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 427 CCTGTTTCAGCATCTTC 443
||| ||||| |||||||
Db 17 CCTCTTTCAACATCTTC 1

RESULT 69
AAA18631
ID AAA18631 standard; RNA; 17 BP.
XX
AC AAA18631;
XX
DT 19-JUN-2000 (first entry)
XX
DE Human TIE-2 substrate sequence SEQ ID NO:1857.
XX
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS Homo sapiens.
XX
PN WO9950403-A2.
XX
PD 07-OCT-1999.
XX
PF 24-MAR-1999; 99WO-US006507.
XX
PR 27-MAR-1998; 98US-0079678P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
XX
DR WPI; 1999-591315/50.
XX
PT Novel ribozymes for modulating the synthesis, expression and/or stability
PT of an mRNA encoding an angiogenic factors.
XX
PS Claim 56; Page 107; 305pp; English.
XX
CC The present invention describes enzymatic nucleic acid molecules with RNA
CC cleaving activity, which specifically cleave RNA encoded by an aryl
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC and AAA19155 to AAA19222 represent their corresponding target sequences;
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC AAA21596 to AAA21688 represent their corresponding target sequences;
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC AAA23422 represent their corresponding target sequences. The ribozymes of
CC the invention are used for modulating the synthesis, expression and/or
CC stability of an mRNA encoding angiogenic factor, especially ARNT,
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC especially used to treat cancer, diabetic retinopathy, age related
CC macular degeneration (ARMD), inflammation, and arthritis, as well as
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ Sequence 17 BP; 9 A; 4 C; 2 G; 0 T; 2 U; 0 Other;

Query Match 1.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 70;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 885 AATCAGATCCATGAAGC 901
||:|| |:||| |||||
Db 1 AAUCAAAUCCAAGAAGC 17

RESULT 70
AAA20854/c
ID AAA20854 standard; RNA; 17 BP.
XX
AC AAA20854;
XX
DT 19-JUN-2000 (first entry)
XX
DE Integrin alpha 6 subunit substrate sequence SEQ ID NO:4080.
XX
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS Homo sapiens.
XX
PN WO9950403-A2.
XX
PD 07-OCT-1999.
XX
PF 24-MAR-1999; 99WO-US006507.
XX
PR 27-MAR-1998; 98US-0079678P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
XX

SCORE OVER LENGTH SEARCHES

Attached is a score over length search. This search was developed to overcome limitations in most standard search systems which favor large sequences with high scoring, but lesser overall identity over smaller sequences with higher overall identity. This search is especially useful for relatively small nucleic acid or polypeptide target sequences (antisense, fragments, probes, primers, RNAi, epitopes, haptens, etc.) claimed functionally via a form of hybridization and/or identity language and having defined upper and lower polynucleotide and or polypeptide length limits.

The score over length search is performed by first running the query sequence using examiner-specified identity and polynucleotide or protein length limit parameters, and saving 65,000 hits and 0 alignments from each desired database. The resulting output is reformatted using a Microsoft Word macro and is imported into Excel. The summary table data are then sorted by the ratio of score of each hit sequence divided by its length and the accession numbers for all hits below the examiner's desired score over length parameters are deleted. The remaining accession numbers are used to pull the corresponding sequences from the databases into subdatabases enriched for good hits and the query sequence is re-run against these subdatabases to yield the final results.

The score over length cutoff for this search is 80%.

Examiner Please Note: This cover sheet should be included when submitting results to be scanned.